A Phase 3 Placebo-controlled, Double-blind, Randomized, Parallel-group Study to Evaluate the Efficacy in Primary and Secondary Dysmenorrhea and the Long-term Safety of DSG/EE 150/20 using a Flexible Extended Regimen of Administration - DSG/EE 150/20

开始日期2023-07-21

申办/合作机构-

NCT03354494

/ CompletedN/AIIT

Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa for Ovarian Stimulation in Donors

Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th stimulation day until ovulation induction with a bolus of another injection of a gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone (rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception, avoiding the LH surge.
In donors, by administering a single injection of FSH-CTP and oral desogestrel since the first menstruation day, the total number of injections administered is reduced and less discomfort is experienced without adverse impact on ovarian response.
Other authors have reported good results using similar synthetic progestins (Medroxyprogesterone, dihydrogesterone, and natural progesterone).
No description of the hormonal and ovarian response under this protocol has been published. Direct comparison between this novel protocol and the classical GnRH- antagonist plus daily gonadotropins has not been reported.

开始日期2016-01-01

申办/合作机构-

NCT01446211

/ Terminated临床3期

Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)

The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive therapy. Further, to evaluate the safety and quality of life of gusperimus treatment compared to standard treatment in patients with relapse of Wegener Granulomatosis receiving glucocorticoids.

开始日期2011-11-01

申办/合作机构

Nordic Pharma SAS

100 项与盐酸胍立莫司相关的临床结果

登录后查看更多信息

100 项与盐酸胍立莫司相关的转化医学

登录后查看更多信息

100 项与盐酸胍立莫司相关的专利（医药）

登录后查看更多信息

1,099

项与盐酸胍立莫司相关的文献（医药）

2025-08-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

DSG2 attenuates gemcitabine efficacy through PTX3 in lung adenocarcinoma

Article

作者: William, Bianca Tobias ; Ta, Hoang Dang Khoa ; Lin, Che-Wei ; Lin, Jo-Ying ; Wang, Chin-Chou ; Liao, Pin-Chen ; Wang, Ju-Ming ; Ho, Yu-Fang ; Dey, Sanskriti ; Wang, Shao-An ; Xuan, Do Thi Minh ; Ko, Ching-Chung ; Wang, Wei-Jan ; Kumar, Sachin ; Wang, Chih-Yang ; Shen, Wan-Jou

Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer, often diagnosed at an advanced stage with poor prognosis and limited treatment options. The Desmoglein (DSG) family plays a crucial role in maintaining cell adhesion and tissue integrity. Upregulation of DSG proteins has been implicated in tumorigenesis, invasion, and metastasis across various cancers. However, the role of DSG in lung cancer, particularly as a biomarker influencing the efficacy of anti-cancer drugs, remains unclear. In this study, DSG2 was significantly overexpressed in LUAD tumor tissues and correlated with poor prognosis, as revealed by TCGA database analysis. Additionally, analyses of single-cell sequencing, KEGG, and GSEA multi-omics databases demonstrated that DSG2 modulates multiple oncogenic pathways, particularly the apoptosis pathway, with a strong positive correlation between DSG2 and PTX3 expression. In vitro experiments showed that DSG2 knockdown enhanced gemcitabine-induced apoptosis by downregulating the NFκB/STAT3/PTX3 signaling axis. Furthermore, adding recombinant PTX3 protein in DSG2 knockdown cells restored STAT3 activation, reducing gemcitabine efficacy, indicating that DSG2 contributes to gemcitabine resistance through PTX3-mediated mechanisms. This study identifies DSG2 as a critical mediator of gemcitabine resistance in LUAD through its regulation of the PTX3/NFκB/STAT3 pathway. The findings suggest that targeting DSG2 could enhance the therapeutic efficacy of gemcitabine in LUAD patients, offering a novel therapeutic strategy and biomarker for overcoming chemoresistance in this aggressive cancer subtype.

2025-06-01·Pain and Therapy

Evaluating the Real-World Use of Topical Diclofenac Sodium Gel 1% Using US Longitudinal Electronic Health Records Database: A study supporting OTC switch

Article

作者: Barbone, Francis P ; Petruschke, Richard ; Revel, Frédérique Bariguian ; Nicholson, Karin ; Sicignano, Nicholas M ; Edison, Jess D

INTRODUCTION:

Musculoskeletal conditions are a significant health challenge and second leading cause of disability worldwide. Diclofenac sodium topical gel 1% (DSG1%) provides effective relief of arthritis pain. While clinical studies show that DSG1% is safe and well-tolerated, long-term safety and tolerability in real-world settings are limited. This study aimed to profile users and prescribers of DSG1% and to evaluate its safety and tolerability over a screening period of 8.5 years with an average follow-up of nearly 1 year. The focus was on patients with risk factors and comorbidities, especially those taking concomitant medication in addition to topical nonsteroidal anti-inflammatory drugs (NSAIDs).

METHODS:

This retrospective, longitudinal cohort study used the US Department of Defense (DoD) electronic health records (EHR) database. The database included 521,593 individuals with ≥ 1 prescription for DSG1% for either indicated or non-indicated conditions with mean (standard deviation; SD) follow-up of 348.4 (562.4) days. The primary outcome measure assessed the incidence of predefined events of interest (EOIs), including gastrointestinal, hepatic, renal diseases, cardiovascular events, hypertension, skin reaction, misuse, abuse, and death (all-cause mortality).

RESULTS:

The average age of subjects was 56.7 years (SD = 18.1), with women comprising 60.4% of population. During study-period, 74.2% of subjects experienced no adverse EOIs after initiating treatment with DSG1%. Among the remaining 25.8%, average time to first EOI was 244.0 (SD = 368.6) days. Notably, the frequency of reported EOIs increased with age. Additionally, subjects with conditions such as rheumatoid arthritis, systemic lupus erythematosus, or diabetes had a higher incidence of cardiovascular EOIs.

CONCLUSIONS:

The study results indicate that DSG demonstrated a favorable safety profile, particularly for patients with comorbidities and high-risk factors and when used with other medications. Despite an older population and high baseline risk factors (93%), only 26% DSG1% users experienced a predefined EOI, observed on average 244.0 (368.6) days from index date. These findings confirm the long-term tolerability of topical DSG1% for musculoskeletal disorders.

2025-05-01·CHEMISTRY & BIODIVERSITY

Unveiling 8,12‐Dimethoxysanguinarine: A Potent Inhibitor of Breast Cancer Metastasis via Fibronectin 1 Downregulation

Article

作者: Xi, Xiuli ; Huang, Xueshuang ; Zhang, Mingli ; Yang, Peng ; Qi, Yuxin

ABSTRACT:

This study investigated the effects of 8,12‐dimethoxysanguinarine (DSG) from Eomecon chionantha Hance on the malignant biological activity of breast cancer cells. RNA‐sequencing measure analysis revealed that metastasis‐related genes were significantly downregulated in DSG‐treated MCF‐7 cells. DSG significantly inhibits the migration ability in MCF‐7 cells. Molecular docking studies demonstrated significant interactions between DSG and the Fibronectin 1 (FN1) protein, with a binding energy of ‐8.91 kcal/mol. Additionally, FN1 messenger RNA expression was significantly upregulated in 1085 breast tumor samples compared to normal tissue in the Cancer Genome Atlas Breast Invasive Carcinoma Collection dataset. DSG also suppressed MCF‐7 cell metastasis by downregulating FN1 expression. Furthermore, DSG was identified as a promising candidate based on absorption distribution metabolism excretion toxicity and drug‐likeness assessments. Combination studies indicated that DSG synergized with the conventional chemotherapeutic agent doxorubicin to suppress MCF‐7 cell migration, as confirmed by wound‐healing and transwell assays. Collectively, these findings suggest that DSG may serve as a potential agent for inhibiting breast cancer cell metastasis by decreasing FN1 expression.

项与盐酸胍立莫司相关的新闻（医药）

2022-07-14

·生物探索

“肿瘤克星”CAR-T疗法再升级！未来或能实现百病皆可CAR-T

摘要：2021年，120万一针的“天价”CAR-T由于价格高昂迅速成为业界的关注焦点，一时间成为话题之王。复星凯特的“奕凯达”、药明巨诺的“贝诺达”先后获批，传奇生物自主研发的“西达基奥伦赛”成为首个申请美国上市的中国CAR-T产品，驯鹿医疗的CT120获美国FDA孤儿药认定，成为全球首款全人源双靶点CAR-T产品。多个产品先后获批，2021年可谓是我国的CAR-T元年。既然CAR-T连医学难题“肿瘤”都可攻克，其治疗领域是否可以得到拓展？自2017年首款CAR-T细胞疗法上市以来，细胞治疗时代正式开启，在多种肿瘤治疗中取得了很好的临床效果，可用靶点数量也正迅速增加。CAR-T在肿瘤治疗领域取得的成功，助长了科学和临床对使用CAR-T作为其他类型疾病治疗方法的兴趣，他们试图从不同的角度去探讨CAR-T细胞疗法的未来发展趋势。近日，Biomedicines发表了一项题为“Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections”的综述，在这篇综述中，研究人员通过关注CAR-T在肿瘤治疗领域之外的疾病，比如自身免疫性疾病和病毒感染，包括SARS-CoV-2，从全新的角度概述了CAR-T细胞疗法的现代趋势和最新发展[1]。图1 研究成果（图源：Biomedicines）CAR-T细胞疗法全称Chimeric antigen receotor T cell therapy，即嵌合抗原受体T细胞疗法。其原理是采集患者自身的T细胞，在体外通过基因技术对其进行改造，装载上具有识别肿瘤抗原的受体和共刺激分子，同时将其进行体外扩增之后再次输回患者体内，使其能够有效识别并更加精准地杀伤肿瘤细胞。尽管病因不同，但部分疾病的发病机制可能与肿瘤存在相似之处，这些共性可能使它们能够通过CAR-T疗法获得治疗。此外，在很多情况下，人类免疫系统会因疾病的发生而出现部分功能障碍，CAR-T则可以作为人类免疫系统的强大替代品，对人体起到一定保护作用。CAR-T细胞与自身免疫性疾病很多自身免疫性疾病（Autoimmune diseases，AIDs）的发病机制仍尚未得到确定，但可以确定的是，T细胞耐受失败在这类疾病的发病过程中起着重要作用。AID中免疫自我耐受性丧失的潜在机制包括激活自身反应性B细胞，从而产生促进组织损伤的自身抗体，以及抑制细胞毒性或调节性T细胞。嵌合自身抗体受体（Chimeric autoantibody receptor，CARR）T细胞靶向自身反应性B细胞表面的自身抗体蛋白，只针对携带特定自身抗体的免疫细胞有选择性细胞毒性，而不会导致免疫抑制。因此，这种细胞可直接消除表面免疫球蛋白记忆B细胞，间接消除产生致病性自身抗体的短暂浆细胞。此外，由于自身免疫性疾病中调节性T细胞（Tregs）在AID中通常受到抑制，研究人员通过将FOXP3转导到T细胞形成CAR-Tregs，以调节患者体内Tregs的功能和活力。图2 嵌合自身抗体受体和嵌合抗原受体活性机制（图源：Biomedicines）已经有研究使用CARR-T细胞治疗寻常型天疱疮（Pemphigus vulgaris，PV），这是一种自身免疫性疾病，由针对角质形成细胞粘附蛋白Dsg3的自身抗体引起。研究人员利用CARR-T细胞的原理设计出Dsg3-CARRT细胞，将其输入PV小鼠模型中，观察到该细胞疗法在PV小鼠模型体内显示出抗Dsg3 B细胞的特异性消除，同时未出现任何不良反应。表1 CAR-T细胞疗法在肿瘤学之外的临床试验列表表格来源：Biomedicines除此以外，CAR-T细胞疗法还被应用于研究血友病、1型糖尿病、多发性硬化症、全身性重症肌无力、系统性红斑狼疮、视神经脊髓炎谱系障碍等自身免疫性疾病的治疗中。CAR-T细胞疗法与传染性疾病慢性乙型肝炎病毒（Hepatitis B virus，HBV）患者通常免疫力低下，长期发展下去很有可能会导致肝癌的发生。基于CAR-T细胞疗法，研究人员设计了一种能特异性识别乙肝病毒表面抗原（Hepatitis B virus surface antigen，HBsAg）的CAR-T细胞，在体外评估了其识别HBV+细胞和HBsAg颗粒的能力，在人肝嵌合小鼠模型中检测其对HBV感染的肝细胞的功效。结果表明，抗HBsAg-CAR T细胞在体外可识别HBsAg颗粒和HBV+细胞，并且在小鼠体内可有效降低HBV-DNA和HBsAg水平。慢性丙型肝炎病毒（Hepatitis C virus，HCV）感染是对当前治疗无反应的终末期慢性感染患者进行肝移植的医学指征。对于很多HCV患者来说，治疗后再次感染的风险仍然很高，这意味着需要开发出有效的替代性疗法。为此，研究人员设计了可识别HCV E2糖蛋白（宿主免疫反应的主要靶标）的CAR-T细胞，结果表明抗HCV/E2 CAR-T细胞对HCV感染的细胞表现出显著的细胞毒性。此外，还有更多研究人员试图探索CAR-T细胞疗法在其他病毒传染性疾病中的作用。比如，人类巨细胞病毒感染以及甲型流感病毒感染。以上研究为进一步探索CAR-T细胞疗法在各种传染性疾病中的治疗提供了依据。CAR-T细胞疗法与其他难治性疾病艾滋病是一种获得性免疫缺陷综合征，由人免疫缺陷病毒引起，发病缓慢，潜伏期可长达15年，死亡率极高。至今，艾滋病仍然是世界性医疗难题，一旦感染病毒无法治愈，只能通过抗病毒治疗控制病情的发生及发展。由于CD8+ T细胞对HIV-1的细胞毒性在控制HIV-1感染中起着关键作用，也因此为将CAR-T细胞疗法用于HIV-1的治疗提供了有效途径。抗HIV-1 CAR-T细胞的治疗靶点为HIV感染细胞表面表达的HIV包膜糖蛋白的gp120区域。研究人员设计了CD4+ CAR-T细胞，经过体外试验，研究人员发现，CD4+ CAR-T细胞能够有效抑制HIV病毒的复制，同时破坏了HIV病毒感染的T细胞。此外，研究人员发现，接受CAR-T细胞疗法治疗的患者，其病毒反弹率较低，肠道HIV DNA显著减少，这表明CD4+ CAR-T细胞确实可以影响组织病毒库。图3 CAR-T细胞疗法在艾滋病治疗中的应用（图源：Biomedicines）除了艾滋病，CAR-T细胞疗法也被应用于COVID-19的治疗中。研究人员试图开发CAR-NK细胞以靶向具有CR3022 scFv结构域的SARS-CoV-2刺突蛋白，通过体外试验，他们发现CR3022 CAR-NK细胞能够消除SARS-CoV-2感染的细胞。除此之外，评估双特异性NKG2D-ACE2 CAR-NK细胞疗法的临床试验（图4）也正在进行中。图4 CAR-T细胞疗法在COVID-19治疗中的应用（图源：Biomedicines）从以上研究可以看出，随着对各种病理学及其分子机制的理解和认识不断发展，CAR-T细胞免疫疗法在医疗上的应用将远远超出肿瘤领域范畴。越来越多的分子被证实为多种疾病的治疗靶点，这使得CAR-T细胞疗法将成为一种有吸引力且极具前景的治疗选择。表2 可以通过CAR-T细胞疗法治疗的疾病列表和相应的靶点表格来源：Biomedicines从肿瘤到自身免疫性疾病，再到各种传染性疾病，CAR-T细胞疗法的应用范围正在不断拓展，相信随着疾病靶点的不断增加以及CAR-T细胞技术的不断升级，未来或许会有更多难治性疾病可以通过CAR-T细胞疗法得以治疗，实现百病且可CAR-T。题图来源：DONLIN LABORATORY，仅用于学术交流。撰文|木子久排版|文竞择 End 参考资料：[1]Zmievskaya E, Valiullina A, Ganeeva I, et al. Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines. 2021 Jan 9;9(1):59. doi: 10.3390/biomedicines9010059. PMID: 33435454; PMCID: PMC7827151. 本文系生物探索原创，欢迎个人转发分享。其他任何媒体、网站如需转载，须在正文前注明来源生物探索。往期精选围观“甜蜜的毒药”：这种常喝饮料致肝癌风险增加高达78%！热文『麦趣尔』牛奶中检出的『丙二醇』，是为何物？对身体有何影响？热文福奇：服用Paxlovid治疗新冠，转阴3天后复阳，症状却更严重！热文全球感染率最高的感染病，50%中国人中招，共餐、接吻更易感染？热文逆龄抗衰还可治疗抑郁！「粪便」入药真的有科学依据？点击“阅读原文”，了解更多~

基因疗法抗体孤儿药细胞疗法免疫疗法突破性疗法

100 项与盐酸胍立莫司相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸胍立莫司	L04AA19	DB12991

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾移植排斥反应	日本	Nippon Kayaku Co., Ltd.	1994-01-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多发性硬化症	申请上市	法国	Nippon Kayaku Co., Ltd.	-
多发性硬化症	申请上市	德国	Nippon Kayaku Co., Ltd.	-
肉芽肿伴多血管炎	临床3期	德国	Nordic Ltd.	-
肉芽肿伴多血管炎	临床3期	西班牙	Nordic Ltd.	-
肉芽肿伴多血管炎	临床3期	瑞典	Nordic Ltd.	-
肉芽肿伴多血管炎	临床3期	英国	Nordic Ltd.	-
狼疮性肾炎	临床2期	捷克	Nippon Kayaku Co., Ltd.	2003-10-01
狼疮性肾炎	临床2期	德国	Nippon Kayaku Co., Ltd.	2003-10-01
肿瘤	临床2期	美国	Nippon Kayaku Co., Ltd.	-
肿瘤	临床2期	日本	Nippon Kayaku Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00709722 (Pubmed \| Arthritis Res Ther)	临床1/2期	狼疮性肾炎	21	15-deoxyspergualin	蓋製顧廠齋遞憲壓鹽鬱(觸鑰鑰醖艱製繭淵簾範) = Five patients dropped out due to adverse events or serious adverse events including fever, leukopenia, oral candidiasis, herpes zoster or pneumonia 構選顧簾製齋膚醖鑰憲 (製鹽觸遞醖觸窪選蓋齋 ) 更多	-	2011-04-01
EULAR2004	临床1/2期	肾小球肾炎	3	15-Deoxyspergualin (15-DSG)	壓範襯鹽製糧憲築觸網(繭壓襯襯糧夢構壓襯製) = No SAE were observed 艱糧鬱簾觸觸網鏇廠憲 (鹹夢鹽糧淵範壓餘淵憲 )	积极	2004-06-09